Understanding FDA regulatory requirements for investigational new drug applications for sponsor-investigators

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

Clinical investigators invoke a number of specific regulatory requirements if their study includes use of a pharmaceutical agent. Studies using a drug that has not been approved by the Food and Drug Administration (FDA) or for indications not in the approved labeling may require filing an Investigational New Drug (IND) application with the FDA. If a study meets specific regulatory exemption criteria, then an IND may not be needed. Individual investigators may meet the FDA definition of a sponsor-investigator, in which case the application process is generally less complicated than for commercial sponsors, and this review addresses only this circumstance. Filing an IND requires completion of 3 sets of forms: 1 detailing the study (FDA Form 1571), 1 providing information about the investigator and study site (FDA Form 1572), and 1 certifying that the study is registered in the national database of clinical trials (FDA Form 3674). If the IND is approved, the study may begin 30 days after the FDA acknowledges receipt and assigns an IND. If the FDA requires additional information or if the study is placed on a Bclinical hold, [ the study must not proceed. While the IND is active, the investigator must also continue to meet a set of regulations for monitoring the study and reporting to the FDA.

Original languageEnglish (US)
Pages (from-to)688-694
Number of pages7
JournalJournal of Investigative Medicine
Volume57
Issue number6
DOIs
StatePublished - Aug 2009

Fingerprint

Investigational New Drug Application
Investigational Drugs
United States Food and Drug Administration
Research Personnel
Pharmaceutical Preparations
Labeling
Monitoring

Keywords

  • Federal regulations
  • Food and drug administration
  • Investigational drug studies
  • Investigational new drug
  • Sponsor-investigator

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)
  • Medicine(all)

Cite this

@article{3d189e5960e1471ca697633ef4e2c7fb,
title = "Understanding FDA regulatory requirements for investigational new drug applications for sponsor-investigators",
abstract = "Clinical investigators invoke a number of specific regulatory requirements if their study includes use of a pharmaceutical agent. Studies using a drug that has not been approved by the Food and Drug Administration (FDA) or for indications not in the approved labeling may require filing an Investigational New Drug (IND) application with the FDA. If a study meets specific regulatory exemption criteria, then an IND may not be needed. Individual investigators may meet the FDA definition of a sponsor-investigator, in which case the application process is generally less complicated than for commercial sponsors, and this review addresses only this circumstance. Filing an IND requires completion of 3 sets of forms: 1 detailing the study (FDA Form 1571), 1 providing information about the investigator and study site (FDA Form 1572), and 1 certifying that the study is registered in the national database of clinical trials (FDA Form 3674). If the IND is approved, the study may begin 30 days after the FDA acknowledges receipt and assigns an IND. If the FDA requires additional information or if the study is placed on a Bclinical hold, [ the study must not proceed. While the IND is active, the investigator must also continue to meet a set of regulations for monitoring the study and reporting to the FDA.",
keywords = "Federal regulations, Food and drug administration, Investigational drug studies, Investigational new drug, Sponsor-investigator",
author = "Holbein, {M. E Blair}",
year = "2009",
month = "8",
doi = "10.231/JIM.0b013e3181afdb26",
language = "English (US)",
volume = "57",
pages = "688--694",
journal = "Journal of Investigative Medicine",
issn = "1081-5589",
publisher = "Lippincott Williams and Wilkins",
number = "6",

}

TY - JOUR

T1 - Understanding FDA regulatory requirements for investigational new drug applications for sponsor-investigators

AU - Holbein, M. E Blair

PY - 2009/8

Y1 - 2009/8

N2 - Clinical investigators invoke a number of specific regulatory requirements if their study includes use of a pharmaceutical agent. Studies using a drug that has not been approved by the Food and Drug Administration (FDA) or for indications not in the approved labeling may require filing an Investigational New Drug (IND) application with the FDA. If a study meets specific regulatory exemption criteria, then an IND may not be needed. Individual investigators may meet the FDA definition of a sponsor-investigator, in which case the application process is generally less complicated than for commercial sponsors, and this review addresses only this circumstance. Filing an IND requires completion of 3 sets of forms: 1 detailing the study (FDA Form 1571), 1 providing information about the investigator and study site (FDA Form 1572), and 1 certifying that the study is registered in the national database of clinical trials (FDA Form 3674). If the IND is approved, the study may begin 30 days after the FDA acknowledges receipt and assigns an IND. If the FDA requires additional information or if the study is placed on a Bclinical hold, [ the study must not proceed. While the IND is active, the investigator must also continue to meet a set of regulations for monitoring the study and reporting to the FDA.

AB - Clinical investigators invoke a number of specific regulatory requirements if their study includes use of a pharmaceutical agent. Studies using a drug that has not been approved by the Food and Drug Administration (FDA) or for indications not in the approved labeling may require filing an Investigational New Drug (IND) application with the FDA. If a study meets specific regulatory exemption criteria, then an IND may not be needed. Individual investigators may meet the FDA definition of a sponsor-investigator, in which case the application process is generally less complicated than for commercial sponsors, and this review addresses only this circumstance. Filing an IND requires completion of 3 sets of forms: 1 detailing the study (FDA Form 1571), 1 providing information about the investigator and study site (FDA Form 1572), and 1 certifying that the study is registered in the national database of clinical trials (FDA Form 3674). If the IND is approved, the study may begin 30 days after the FDA acknowledges receipt and assigns an IND. If the FDA requires additional information or if the study is placed on a Bclinical hold, [ the study must not proceed. While the IND is active, the investigator must also continue to meet a set of regulations for monitoring the study and reporting to the FDA.

KW - Federal regulations

KW - Food and drug administration

KW - Investigational drug studies

KW - Investigational new drug

KW - Sponsor-investigator

UR - http://www.scopus.com/inward/record.url?scp=70349247863&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=70349247863&partnerID=8YFLogxK

U2 - 10.231/JIM.0b013e3181afdb26

DO - 10.231/JIM.0b013e3181afdb26

M3 - Article

C2 - 19602987

AN - SCOPUS:70349247863

VL - 57

SP - 688

EP - 694

JO - Journal of Investigative Medicine

JF - Journal of Investigative Medicine

SN - 1081-5589

IS - 6

ER -